查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1959925

止咳藥市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類別、給藥途徑、年齡層、最終用戶、地區和競爭格局分類，2021-2031年

Antitussive Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Drug Class, By Route of Administration, By Age Group, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球止咳藥市場預計將從 2025 年的 16.7 億美元成長到 2031 年的 22.6 億美元，複合年成長率為 5.17%。

這些藥物專門用於抑制咳嗽反射，其作用機制包括作用於中樞神經系統的咳嗽中樞或靶向周圍神經系統，因此是治療方法乾咳、無痰咳嗽的主要藥物。市場成長的主要促進因素是全球老化人口中慢性呼吸系統疾病盛行率的上升，以及急性呼吸道感染疾病發生率的增加。此外，快速的都市化及其導致的日益嚴重的環境污染也加劇了呼吸系統疾病的發生，從而維持了對有效止咳藥物的強勁需求。

市場概覽
預測期 2027-2031
市場規模：2025年 16.7億美元
市場規模：2031年 22.6億美元
複合年成長率：2026-2031年 5.17%
成長最快的細分市場 周邊促效劑
最大的市場 北美洲

儘管成長前景強勁，但由於鴉片類藥物製劑本身存在濫用和誤用的風險，市場面臨日益嚴格的監管審查，因此也面臨巨大的挑戰。歐洲自我護理產業協會 (AESCIA) 發布的《2025 年報告》指出，屆時將有 47 億劑用於治療咳嗽、感冒等輕微健康問題的非處方藥流通，這凸顯了消費者對這些產品的高度依賴。然而，各地實施更嚴格的監管措施，以及某些止咳成分被重新歸類為處方箋藥，可能會阻礙產品的供應，並限制整體市場擴張。

市場促進因素

慢性及急性呼吸系統疾病的日益普遍是全球止咳藥市場的主要驅動力。病毒感染的周期性爆發和持續的感染疾病負擔推動了這一成長，進而直接產生了對止咳治療的需求。止咳藥的需求顯著增加，尤其是在流感季，咳嗽管理變得特別迫切。例如，美國疾病管制與預防中心 (CDC) 於 2025 年 5 月發布的關於 2024-2025 年流感季暫定負擔的報告估計，美國流感病例數將在 4,700 萬至 8,200 萬之間，這意味著龐大的患者群體需要緩解症狀。此外，慢性疾病也保證了季節性高峰以外的持續市場需求。正如世界衛生組織 (WHO) 於 2025 年 11 月發布的《2025 年全球結核病報告》所示，2024 年約有 1,070 萬人將患有結核病，需要持續的症狀管理。

同時，消費者對非處方止咳藥的需求不斷成長，以及自我治療方式的普及，正顯著推動市場收入的成長。消費者越來越重視非處方箋糖漿和潤喉糖在緩解輕微呼吸道疾病方面的經濟性和便利性，而較少尋求醫療協助。這種消費行為正在提升大型製藥公司醫療保健部門的表現。例如，寶潔公司在2025年8月發布的《2025年年度報告》中指出，由於消費者持續依賴值得信賴的自我護理產品，其個人健康照護部門（包括其領先的呼吸系統品牌）實現了中等個位數的有機銷售成長。這一趨勢在新興經濟體尤為明顯，這些地區不斷擴張的零售網路使患者能夠輕鬆獲得止咳藥，非處方產品正成為全球市場的基石。

市場挑戰

對止咳藥處方的嚴格監管嚴重阻礙了市場成長。世界各國政府都在實施嚴格的監管措施，以降低鴉片類藥物和其他強效止咳藥帶來的成癮和濫用風險。這些日益嚴格的監管措施往往將有效的非處方藥重新歸類為處方箋藥，嚴重限制了公眾取得這些藥物的途徑。此類監管措施為消費者的購買過程帶來了許多不便，迫使患者選擇就醫並承擔相關費用，而非便捷的自我護理方案，直接降低了生產商的銷售量。

這些限制性政策背後的主要驅動力是濫用案例的不斷發生，凸顯了嚴格市場監管的必要性。根據消費者保健產品協會（CHPA）2025年的數據，高中二年級學生非醫療用途使用咳嗽和感冒藥的比例將達到5.1%，這凸顯了產品被挪作娛樂用途這一長期存在的問題。這項統計數據強化了監管機構維持高進入門檻的決心，導致製造商面臨通路和收入成長受阻的困境。嚴格的合規環境阻礙了這些必需治療方法的商業性擴充性。

市場趨勢

P2X3受體拮抗劑在慢性咳嗽治療領域的商業化正蓬勃發展，有望解決難治性疾病患者亟待解決的重大醫療需求。與傳統的中樞性鴉片類藥物不同，這些創新藥物針對周邊受體，抑制高敏性咳嗽反射，且不會引起鎮靜或依賴性。這為對標準治療無效的患者提供了必要的替代方案。在成功完成後期臨床試驗後，這種標靶治療方法即將上市。尤其值得一提的是，FirstWord Pharma於2025年3月發表的報導「Trevi菌株在難治性慢性咳嗽治療中備受期待」的文章，重點介紹了這類新興藥物的潛在療效。文章指出，在IIb期SOOTHE試驗中，P2X3拮抗劑camlipixant與安慰劑相比，可使24小時咳嗽頻率降低34%。

同時，人工智慧驅動的診斷與數位化咳嗽監測的融合正在革新評估方法，使其從主觀的患者報告轉向客觀的數據量化。先進的演算法正被用於透過穿戴式技術被動地追蹤咳嗽模式和頻率，從而為臨床試驗和遠端患者監護提供檢驗的終點指標。這項技術進步解決了呼吸系統研究中長期以來患者自我報告數據不可靠的難題。例如，Hyfe公司於2024年10月發布的一份題為《自動化人工智慧驅動的Hyfe連續咳嗽監測系統的檢驗與準確性》的報告證實，該公司的人工智慧系統在546小時的連續監測中，對咳嗽事件的檢測靈敏度達到了90.4%，證明了數位生物標記在真實臨床環境中的可靠性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球止咳藥市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物分類（周邊促效劑、中樞促效劑、其他）
    • 給藥途徑（吸入、口服、其他）
    • 依年齡層別（老年人、兒童、成人）
    • 依最終使用者（居家醫療、醫院/專科診所、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美止咳藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲止咳藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區止咳藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲止咳藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲止咳藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球止咳藥市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Teva Pharmaceutical Industries Ltd.
  • Intas Pharmaceuticals Ltd.
  • Bayer AG
  • Ipca Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Hikma Pharmaceuticals PLC
  • Unique Pharmaceuticals Limited
  • Cipla Inc.
  • Viatris Inc.
  • Aurobindo Pharma

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17246

The Global Antitussive Drugs Market is projected to expand from USD 1.67 Billion in 2025 to USD 2.26 Billion by 2031, registering a CAGR of 5.17%. These pharmaceutical agents are specifically formulated to inhibit the coughing reflex, serving as a primary treatment for dry, non-productive coughs by acting on the cough center in the central nervous system or targeting the peripheral nervous system. Market growth is largely fueled by the increasing frequency of acute respiratory tract infections alongside a higher prevalence of chronic respiratory disorders within an aging global demographic. Furthermore, rapid urbanization and the consequent escalation in environmental pollution are leading to more frequent respiratory ailments, thereby maintaining strong demand for effective cough suppression solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.67 Billion
Market Size 2031USD 2.26 Billion
CAGR 2026-20315.17%
Fastest Growing SegmentPeripherally Acting Drugs
Largest MarketNorth America

Despite these positive growth prospects, the market confronts substantial challenges stemming from regulatory scrutiny over opioid-based formulations, given the inherent risks of abuse and misuse. Highlighting the heavy consumer dependence on these products, the Association of the European Self-Care Industry reported in 2025 that the sector distributed 4.7 billion packs of non-prescription medicines for managing minor health issues, including cough and cold. However, the implementation of stricter regulations and the reclassification of specific antitussive ingredients to prescription-only status in various regions threaten to hinder product accessibility and constrain overall market expansion.

Market Driver

The escalating prevalence of both chronic and acute respiratory disorders serves as a primary engine for the Global Antitussive Drugs Market. This growth is driven by the cyclical nature of viral outbreaks and the enduring burden of infectious diseases, which create a direct need for cough suppression therapies. Demand for antitussives notably surges during severe influenza seasons when cough management becomes urgent; for example, the Centers for Disease Control and Prevention's May 2025 report on the preliminary burden of the 2024-2025 flu season estimated between 47 million and 82 million influenza illnesses in the United States, representing a vast patient population seeking symptomatic relief. Additionally, chronic conditions ensure sustained market demand beyond seasonal spikes, as evidenced by the World Health Organization's 'Global Tuberculosis Report 2025' from November 2025, which noted that approximately 10.7 million individuals fell ill with tuberculosis in 2024, necessitating ongoing symptom management.

Concurrently, the increasing demand for Over-the-Counter (OTC) antitussive medications and the rise of self-medication practices are significantly boosting market revenue. Consumers are frequently opting to skip primary care visits for minor respiratory issues in favor of the affordability and convenience offered by non-prescription syrups and lozenges. This consumer behavior is strengthening the financial results of major pharmaceutical health divisions; for instance, Procter & Gamble's '2025 Annual Report' from August 2025 highlighted that their Personal Health Care segment, which includes key respiratory brands, attained mid-single-digit organic sales growth due to continued reliance on trusted self-care products. This trend is especially pronounced in emerging economies, where broader retail access allows patients to readily obtain cough remedies, establishing OTC products as a fundamental pillar of the global market.

Market Challenge

Intense regulatory scrutiny regarding antitussive formulations presents a significant barrier to market growth. Governments worldwide are enforcing strict controls to curb the risks of dependence and abuse linked to opioid-based and other potent cough suppressants. This tightening often leads to the reclassification of effective over-the-counter medications to prescription-only status, which sharply limits their availability to the general public. Such regulatory actions create considerable friction in the consumer purchasing journey, forcing patients to dedicate time and money toward physician consultations instead of accessing convenient self-care solutions, which directly reduces sales volumes for manufacturers.

The ongoing occurrence of misuse incidents acts as the main driver for these restrictive policies, validating the need for stringent market oversight. Data from the Consumer Healthcare Products Association in 2025 indicated that the prevalence rate for nonmedical use of cough and cold medications among 10th graders reached 5.1%, underscoring the persistent problem of product diversion for recreational use. This statistic reinforces the resolve of regulators to uphold high access barriers, subsequently causing manufacturers to struggle with limited distribution channels and suppressed revenue growth as the rigorous compliance environment hampers the commercial scalability of these vital therapies.

Market Trends

The commercialization of P2X3 receptor antagonists for chronic cough is gaining momentum as a means to address the critical unmet needs of patients suffering from refractory conditions. In contrast to traditional centrally acting opioids, these innovative agents target peripheral receptors to suppress the hypersensitized cough reflex without inducing sedation or dependence, providing a necessary alternative for individuals who do not respond to standard treatments. This targeted therapeutic approach is nearing market readiness following successful late-stage clinical validation; notably, a March 2025 article by FirstWord Pharma titled 'Trevi soars on hopes for refractory chronic cough treatment' reported that the P2X3 antagonist camlipixant achieved a 34% placebo-adjusted reduction in 24-hour cough frequency during the Phase IIb SOOTHE trial, highlighting the potential efficacy of this emerging drug class.

In parallel, the integration of AI-driven diagnostics and digital cough monitoring is revolutionizing assessment methods by shifting from subjective patient reports to objective data quantification. Advanced algorithms are increasingly being utilized to passively track cough patterns and frequency through wearable technology, offering verifiable endpoints for clinical trials and remote patient monitoring. This technological advancement addresses the historic unreliability of self-reported data in respiratory research. For example, a report by Hyfe in October 2024, titled 'Validation and Accuracy of the Automated AI-powered Continuous Hyfe Cough Monitoring System,' confirmed that their AI system demonstrated a 90.4% sensitivity in detecting cough events over 546 hours of continuous monitoring, proving the reliability of digital biomarkers in real-world settings.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • Intas Pharmaceuticals Ltd.
  • Bayer AG
  • Ipca Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Hikma Pharmaceuticals PLC
  • Unique Pharmaceuticals Limited
  • Cipla Inc.
  • Viatris Inc.
  • Aurobindo Pharma

Report Scope

In this report, the Global Antitussive Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antitussive Drugs Market, By Drug Class

  • Peripherally Acting Drugs
  • Centrally Acting Drugs
  • Others

Antitussive Drugs Market, By Route of Administration

  • Inhalational
  • Oral
  • Others

Antitussive Drugs Market, By Age Group

  • Geriatric
  • Pediatric
  • Adult

Antitussive Drugs Market, By End-User

  • Homecare
  • Hospitals & Specialty Clinics
  • Others

Antitussive Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antitussive Drugs Market.

Available Customizations:

Global Antitussive Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antitussive Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Peripherally Acting Drugs, Centrally Acting Drugs, Others)
    • 5.2.2. By Route of Administration (Inhalational, Oral, Others)
    • 5.2.3. By Age Group (Geriatric, Pediatric, Adult)
    • 5.2.4. By End-User (Homecare, Hospitals & Specialty Clinics, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Antitussive Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Route of Administration
    • 6.2.3. By Age Group
    • 6.2.4. By End-User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Antitussive Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Age Group
        • 6.3.1.2.4. By End-User
    • 6.3.2. Canada Antitussive Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Age Group
        • 6.3.2.2.4. By End-User
    • 6.3.3. Mexico Antitussive Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Age Group
        • 6.3.3.2.4. By End-User

7. Europe Antitussive Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Route of Administration
    • 7.2.3. By Age Group
    • 7.2.4. By End-User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Antitussive Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Age Group
        • 7.3.1.2.4. By End-User
    • 7.3.2. France Antitussive Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Age Group
        • 7.3.2.2.4. By End-User
    • 7.3.3. United Kingdom Antitussive Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Age Group
        • 7.3.3.2.4. By End-User
    • 7.3.4. Italy Antitussive Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Age Group
        • 7.3.4.2.4. By End-User
    • 7.3.5. Spain Antitussive Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Age Group
        • 7.3.5.2.4. By End-User

8. Asia Pacific Antitussive Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Route of Administration
    • 8.2.3. By Age Group
    • 8.2.4. By End-User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Antitussive Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Age Group
        • 8.3.1.2.4. By End-User
    • 8.3.2. India Antitussive Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Age Group
        • 8.3.2.2.4. By End-User
    • 8.3.3. Japan Antitussive Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Age Group
        • 8.3.3.2.4. By End-User
    • 8.3.4. South Korea Antitussive Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Age Group
        • 8.3.4.2.4. By End-User
    • 8.3.5. Australia Antitussive Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Age Group
        • 8.3.5.2.4. By End-User

9. Middle East & Africa Antitussive Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Route of Administration
    • 9.2.3. By Age Group
    • 9.2.4. By End-User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Antitussive Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Age Group
        • 9.3.1.2.4. By End-User
    • 9.3.2. UAE Antitussive Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Age Group
        • 9.3.2.2.4. By End-User
    • 9.3.3. South Africa Antitussive Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Age Group
        • 9.3.3.2.4. By End-User

10. South America Antitussive Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Route of Administration
    • 10.2.3. By Age Group
    • 10.2.4. By End-User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Antitussive Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Age Group
        • 10.3.1.2.4. By End-User
    • 10.3.2. Colombia Antitussive Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Age Group
        • 10.3.2.2.4. By End-User
    • 10.3.3. Argentina Antitussive Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Age Group
        • 10.3.3.2.4. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Antitussive Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Teva Pharmaceutical Industries Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Intas Pharmaceuticals Ltd.
  • 15.3. Bayer AG
  • 15.4. Ipca Laboratories Ltd.
  • 15.5. F. Hoffmann-La Roche Ltd.
  • 15.6. Hikma Pharmaceuticals PLC
  • 15.7. Unique Pharmaceuticals Limited
  • 15.8. Cipla Inc.
  • 15.9. Viatris Inc.
  • 15.10. Aurobindo Pharma

16. Strategic Recommendations

17. About Us & Disclaimer